Vegetable-based drug could inhibit melanoma

Mar 01, 2009

Compounds extracted from green vegetables such as broccoli and cabbage could be a potent drug against melanoma, according to cancer researchers. Tests on mice suggest that these compounds, when combined with selenium, target tumors more safely and effectively than conventional therapy.

"There are currently no drugs to target the proteins that trigger melanoma," said Gavin Robertson, associate professor of pharmacology, pathology and dermatology, Penn State College of Medicine. "We have developed drugs from naturally occurring compounds that can inhibit the growth of tumors in mice by 50 to 60 percent with a very low dose."

Robertson and his colleagues previously showed the therapeutic potential of targeting the Akt3 protein in inhibiting the development of melanoma. The search for a drug to block the protein led them to a class of compounds called isothiocyanates.

These naturally occurring chemicals found in cruciferous vegetables are known to have certain cancer-fighting properties. However, the potency of these compounds is so low that a successful drug would require large impractical amounts of these compounds.

Instead, the Penn State researchers rewired the compounds by replacing their sulfur bonds with selenium. The result, they believe, is a more potent drug that can be delivered intravenously in low doses.

"Selenium deficiency is common in cancer patients, including those diagnosed with metastatic melanoma," explained Robertson, whose findings appear in the March edition of Clinical Cancer Research. "Besides, selenium is known to destabilize Akt proteins in prostate cancer cells."

To study the effectiveness of the new drug -- isoselenocyanate -- researchers injected mice with 10 million cancer cells. Six days later, when the animals developed large tumors, they were divided into two groups and treated separately with either the vegetable compounds or the compounds supplemented with selenium.

"We found that the selenium-enhanced compounds significantly reduced the production of Akt3 protein and shut down its signaling network," explained Robertson, who is also associate director of translational research and leader of the experimental therapeutics program at Penn State Hershey Cancer Institute. The modified compounds also reduced the growth of tumors by 60 percent, compared to the vegetable-based compounds alone.

When the researchers exposed three different human melanoma cell lines to the two compounds, the selenium-enhanced drug worked better on some cell lines than others. The efficiency was from 30 to 70 percent depending on the cell line.

The exact mechanism of how selenium inhibits cancer remains unclear. However Robertson, who has a filed provisional patent on the discovery, is convinced that the use of naturally occurring compounds that target cancer-causing proteins could lead to more effective ways of treating melanoma.

"We have harnessed something found in nature to target melanoma," said Robertson. "And since we only need tiny amounts to kill the cancer cells, it means even less toxic side-effects for the patient."

Human trials of the new drug are still some years away, but the Penn State researcher envisions a drug that could be delivered either intravenously to treat melanoma, or added to sunscreen lotion to prevent the disease.

Source: Penn State

Explore further: Promising blood biomarkers identified for colorectal cancer: Is a screening blood test within reach?

add to favorites email to friend print save as pdf

Related Stories

Google profit dips to $2.8 bn

7 hours ago

Google said Thursday its profit in the past quarter dipped slightly from a year earlier, even as revenues for the technology giant showed a sharp increase.

Shrinking resource margins in Sahel region of Africa

7 hours ago

The need for food, animal feed and fuel in the Sahel belt is growing year on year, but supply is not increasing at the same rate. New figures from 22 countries indicate falling availability of resources per ...

Recommended for you

Blood biomarker may detect lung cancer

16 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

ACG: Recent increase in incidence of young-onset CRC

Oct 20, 2014

(HealthDay)—The incidence of young-onset colorectal cancer (CRC) is increasing, and the disease is more aggressive pathologically. These findings are being presented at the annual meeting of the American ...

User comments : 3

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
1 / 5 (1) Mar 01, 2009
Some compounds RAISE cell temps., and some lower it. Needs vary in the same body.High temps. accelereate mitosis. Low temps DECELERATE it!
fixer
not rated yet Mar 01, 2009
why bother? If human tests are years away it's already out of date.
Au-Pu
not rated yet Mar 02, 2009
According to a local news report last year, The Royal Prince Alfred Hospital in Sydney Australia ran tests in 2008 where a substance called "Madras Pink" was injected directly into melanomas killing the melanoma within 48 hours.
I have heard nothing more of this experiment since.
It appears that the patients used in this experiment were all advanced melanoma cases.
This could be worth following up.